Drug Trial Radar · NCT04266249
CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy
Last checked: Nov 20, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
2,175
Actual
Start
Mar 13, 2020
Primary completion
Oct 31, 2027
Study completion Dec 31, 2038
Sponsor
- Lead sponsor
- ECOG-ACRIN Cancer Research GroupResearch network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Feb 12, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial studies how well paclitaxel, trastuzumab, and pertuzumab work in eliminating further chemotherapy after surgery in patients with HER2-positive stage II-IIIa breast cancer who have no cancer remaining at surgery (either in the breast or underarm lymph nodes) after pre-operative chemotherapy and HER2-targeted therapy. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Trastuzumab and pertuzumab are both a form of "targeted therapy" because they work by attaching themselves to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When these drugs attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Giving paclitaxel, trastuzumab, and pertuzumab may enable fewer chemotherapy drugs to be given without compromising patient outcomes compared to the usual treatment.
Conditions
- Anatomic Stage II Breast Cancer AJCC v8
- Anatomic Stage IIA Breast Cancer AJCC v8
- Anatomic Stage IIB Breast Cancer AJCC v8
- Anatomic Stage IIIA Breast Cancer AJCC v8
- Invasive Breast Carcinoma
- Prognostic Stage II Breast Cancer AJCC v8
- Prognostic Stage IIA Breast Cancer AJCC v8
- Prognostic Stage IIB Breast Cancer AJCC v8
- Prognostic Stage IIIA Breast Cancer AJCC v8
Interventions
DocetaxelDrug
Given IV
LumpectomyProcedure
Undergo lumpectomy
MastectomyProcedure
Undergo mastectomy
Nab-paclitaxelDrug
Given IV
PaclitaxelDrug
Given IV
PertuzumabBiological
Given IV
Radiation TherapyRadiation
Undergo radiation therapy
TrastuzumabBiological
Given IV
Trastuzumab EmtansineBiological
Given IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recurrence-free survival (RFS)Time frame: Up to 3 years after end of treatment
Locations
1,008 sites in 2 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama
Anchorage Associates in Radiation Medicine
Anchorage, Alaska
Anchorage Radiation Therapy Center
Anchorage, Alaska
Alaska Breast Care and Surgery LLC
Anchorage, Alaska
Alaska Oncology and Hematology LLC
Anchorage, Alaska
Alaska Women's Cancer Care
Anchorage, Alaska
Anchorage Oncology Centre
Anchorage, Alaska
Katmai Oncology Group
Anchorage, Alaska
Providence Alaska Medical Center
Anchorage, Alaska
Fairbanks Memorial Hospital
Fairbanks, Alaska
Kingman Regional Medical Center
Kingman, Arizona
Cancer Center at Saint Joseph's
Phoenix, Arizona
University of Arizona Cancer Center-Orange Grove Campus
Tucson, Arizona
Banner University Medical Center - Tucson
Tucson, Arizona
University of Arizona Cancer Center-North Campus
Tucson, Arizona
Mercy Hospital Fort Smith
Fort Smith, Arkansas
CHI Saint Vincent Cancer Center Hot Springs
Hot Springs, Arkansas
NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro
Jonesboro, Arkansas
CARTI Cancer Center
Little Rock, Arkansas
Mission Hope Medical Oncology - Arroyo Grande
Arroyo Grande, California
PCR Oncology
Arroyo Grande, California
Sutter Auburn Faith Hospital
Auburn, California
Sutter Cancer Centers Radiation Oncology Services-Auburn
Auburn, California
Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California
Providence Saint Joseph Medical Center/Disney Family Cancer Center
Burbank, California
Mills-Peninsula Medical Center
Burlingame, California
Marshall Cancer Center
Cameron Park, California
Sutter Cancer Centers Radiation Oncology Services-Cameron Park
Cameron Park, California
Mercy Cancer Center - Carmichael
Carmichael, California
Mercy San Juan Medical Center
Carmichael, California
Eden Hospital Medical Center
Castro Valley, California
John Muir Medical Center-Concord Campus
Concord, California
Sutter Davis Hospital
Davis, California
Epic Care-Dublin
Dublin, California
Mercy Cancer Center - Elk Grove
Elk Grove, California
Bay Area Breast Surgeons Inc
Emeryville, California
Epic Care Partners in Cancer Care
Emeryville, California
Palo Alto Medical Foundation-Fremont
Fremont, California
Washington Hospital
Fremont, California
Keck Medicine of USC Huntington Beach
Huntington Beach, California
Showing 40 of 1,008 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.